SOAT1 and synovial sarcoma: Other inflammatory diseases, where the use of JAKi seems to be desirable include sarcoidosis (177–180), and Sjögren's syndrome (SS), autoimmune diseases with strong molecular association to the JAK/STAT signaling pathway (181–184).